Skip to main content

Table 1 Institutional guidelines - relative and absolute criteria for discontinuation of IL-2 therapy

From: Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience


Relative criteria

Absolute criteria


Sinus tachycardia, HR 120 – 130

Sinus tachycardia, HR >130

EKG Ischemia

Atrial Fibrillation


Frequent PVCs, bigeminy, ventricular arrhythmia

Elevated cardiac enzymes



Moist desquamation


Diarrhea >1000cc/shift

Refractory vomiting

Unrelenting abdominal pain

Abdominal distension



Hypotension requiring pressors


Guiac-positive stool, sputum or emesis

Frank blood in stools, sputum or emesis

Platelets 30,000 – 50,000/mm3

Platelets < 30,000/mm3



Strong clinical suspicion or documented



Mental status changes

Disorientation, vivid dreams, emotional lability


Resting dyspnea

>4 L oxygen needed for saturations >95%

Crackles present in >1/3 but <1/2 chest

Crackles present in >1/2 chest

40% oxygen mask for saturations >95%

3 – 4 L oxygen for saturations > 95%



Urine output 80 – 160 mL/8 hour

Urine <80 mL/8 hour

Urine < 10 mL/hour

Creatinine ≥ 3 mg/dL

Urine 10 – 20 mL/hour

Creatinine 2.5 – 2.9 mg/dL

Weight Gain

15% over baseline

  1. In the occurrence of any relative criteria the dose is held, corrective action taken and patient re-assessed at next scheduled time. Discontinue therapy if ≥ 3 relative criteria occur or for any one absolute criteria. Discontinue therapy if pressors are needed for hypotension, neurological changes or the scheduled dose has been held on 3 occasions.
  2. HR = heart rate, EKG = electrocardiogram, PVC = premature ventricular contraction).